IFN-alpha-induced apoptosis in hepatocellular carcinoma involves promyelocytic leukemia protein and TRAIL independently of p53.

IFNs are pleiotropic cytokines that have been shown to be important regulators of cell growth. IFN-alpha has recently been recognized to harbor therapeutic potential in prevention and treatment of hepatocellular carcinoma (HCC). However, HCC cells respond differentially to IFN treatment, the mechanism of which is largely unknown. To address this issue, we analyzed the effect of IFN-alpha on different liver tumor cell lines. We found that growth inhibiting effects of IFN-alpha in hepatoma cells require PML-NB induction and, moreover, tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) expression on the mRNA and protein level. RNAi silencing of PML down-regulates TRAIL expression in hepatoma cells and correspondingly blocks IFN-alpha-induced apoptosis. In addition, PML-deficient primary hepatocytes fail to up-regulate TRAIL upon IFN-alpha-treatment in contrast to their wild-type counterparts. These data identify TRAIL as a novel downstream transcriptional target of PML-mediated apoptosis in hepatomas and suggest that PML and TRAIL play important roles in IFN-regulated apoptosis in HCC. Furthermore, the mechanism is independent of the p53 status of the tumor cells. In summary, our results identify central molecules mediating IFN-alpha induced apoptosis in liver tumors, shed light on the differential response of hepatoma cells to IFN exposure and, thus, may contribute to an efficient application of this substance in the treatment of liver cancer.

[1]  P. Salomoni,et al.  New insights into the role of PML in tumour suppression , 2008, Cell Research.

[2]  J. Marrero,et al.  Diagnosis and treatment of hepatocellular carcinoma. , 2008, Gastroenterology.

[3]  Y. Takeda,et al.  Pilot study of combination chemotherapy of S‐1, a novel oral DPD inhibitor, and interferon‐α for advanced hepatocellular carcinoma with extrahepatic metastasis , 2008, Cancer.

[4]  L. Schwartz,et al.  Phase II Trial of Pegylated Interferon-α2b in Patients with Advanced Renal Cell Carcinoma , 2008 .

[5]  V. Tayal,et al.  Cytokines and anti-cytokines as therapeutics--an update. , 2008, European journal of pharmacology.

[6]  H. Walczak,et al.  Biochemical analysis of the native TRAIL death-inducing signaling complex. , 2008, Methods in molecular biology.

[7]  J. Bruix,et al.  Novel advancements in the management of hepatocellular carcinoma in 2008. , 2008, Journal of hepatology.

[8]  H. Yoshiji,et al.  Different tumoricidal effects of interferon subclasses and p53 status on hepatocellular carcinoma development and neovascularization. , 2008, International journal of oncology.

[9]  A. Kibel.  Final results from a national multicenter phase II trial of combination bacillus Calmette-Guérin plus interferon α-2B for reducing recurrence of superficial bladder cancer , 2007 .

[10]  H. Reeves,et al.  The development of targeted therapies for hepatocellular cancer. , 2007, Current pharmaceutical design.

[11]  N. Toyota,et al.  Pretreatment predictor of response, time to progression, and survival to intraarterial 5-fluorouracil/interferon combination therapy in patients with advanced hepatocellular carcinoma , 2007, Journal of gastroenterology.

[12]  J. Mizuguchi,et al.  Interferon-alpha-induced apoptosis via tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-dependent and -independent manner. , 2007, Oncology reports.

[13]  C. Dinney,et al.  Interferon-α Induces TRAIL Expression and Cell Death Via an IRF-1-Dependent Mechanism in Human Bladder Cancer Cells , 2007 .

[14]  T. Kyo,et al.  Treatment with IFNαin vivo up‐regulates serum‐soluble TNF‐related apoptosis inducing ligand (sTRAIL) levels and TRAIL mRNA expressions in neutrophils in chronic myelogenous leukemia patients , 2007, European journal of haematology.

[15]  Ronald Koschny,et al.  The promise of TRAIL—potential and risks of a novel anticancer therapy , 2007, Journal of Molecular Medicine.

[16]  T. Tanimoto,et al.  Role of p53 in the inhibitory effects of interferon-alpha subtypes on proliferation of hepatocellular carcinoma cells. , 2006, Biomedical research.

[17]  Brian J. Smith,et al.  Final results from a national multicenter phase II trial of combination bacillus Calmette-Guérin plus interferon alpha-2B for reducing recurrence of superficial bladder cancer. , 2006, Urologic oncology.

[18]  P. Galle,et al.  Hepatitis C virus core protein inhibits tumor suppressor protein promyelocytic leukemia function in human hepatoma cells. , 2005, Cancer research.

[19]  J. Becker,et al.  STAT5 Contributes to Interferon Resistance of Melanoma Cells , 2005, Current Biology.

[20]  M. Li‐Weber,et al.  Proteasome inhibition sensitizes hepatocellular carcinoma cells, but not human hepatocytes, to TRAIL , 2005, Hepatology.

[21]  P. Krammer,et al.  Transforming growth factor β can mediate apoptosis via the expression of TRAIL in human hepatoma cells , 2005 .

[22]  R. Davis,et al.  PML mediates IFN-α-induced apoptosis in myeloma by regulating TRAIL induction , 2005 .

[23]  W. Stremmel,et al.  Enhanced caspase-8 recruitment to and activation at the DISC is critical for sensitisation of human hepatocellular carcinoma cells to TRAIL-induced apoptosis by chemotherapeutic drugs , 2004, Cell Death and Differentiation.

[24]  P. Pandolfi,et al.  Loss of the tumor suppressor PML in human cancers of multiple histologic origins. , 2004, Journal of the National Cancer Institute.

[25]  B. Williams,et al.  Apoptosis and interferons: Role of interferon-stimulated genes as mediators of apoptosis , 2003, Apoptosis.

[26]  T. Hofmann,et al.  Body language: the function of PML nuclear bodies in apoptosis regulation , 2003, Cell Death and Differentiation.

[27]  B. Seliger,et al.  Upregulation of Major Histocompatibility Complex Class I on Liver Cells by Hepatitis C Virus Core Protein via p53 and TAP1 Impairs Natural Killer Cell Cytotoxicity , 2003, Journal of Virology.

[28]  H. Friess,et al.  Primary human hepatocytes--a valuable tool for investigation of apoptosis and hepatitis B virus infection. , 2003, Journal of hepatology.

[29]  K. Totpal,et al.  Enhanced tumor killing by Apo2L/TRAIL and CPT-11 co-treatment is associated with p21 cleavage and differential regulation of Apo2L/TRAIL ligand and its receptors , 2002, Oncogene.

[30]  M. Smyth,et al.  Increased Susceptibility to Tumor Initiation and Metastasis in TNF-Related Apoptosis-Inducing Ligand-Deficient Mice1 , 2002, The Journal of Immunology.

[31]  S. Koyama,et al.  Expression of TNF-related apoptosis-inducing ligand (TRAIL) and its receptors in gastric carcinoma and tumor-infiltrating lymphocytes: a possible mechanism of immune evasion of the tumor , 2002, Journal of Cancer Research and Clinical Oncology.

[32]  P. Pandolfi,et al.  Role of Promyelocytic Leukemia (Pml) Protein in Tumor Suppression , 2001, The Journal of experimental medicine.

[33]  C. Rauch,et al.  Tumoricidal activity of tumor necrosis factor–related apoptosis–inducing ligand in vivo , 1999, Nature Medicine.

[34]  B. Williams,et al.  Identification of genes differentially regulated by interferon α, β, or γ using oligonucleotide arrays , 1998 .

[35]  D. Israeli,et al.  p53 Activates the CD95 (APO-1/Fas) Gene in Response to DNA Damage by Anticancer Drugs , 1998, The Journal of experimental medicine.

[36]  Williams,et al.  Identification of genes differentially regulated by interferon a , b , or g using oligonucleotide arrays , 1998 .

[37]  P. Pandolfi,et al.  The acute promyelocytic leukaemia-associated PML gene is induced by interferon. , 1995, Oncogene.

[38]  P. Thomas,et al.  Type I interferon resistance in a colorectal cancer cell line is associated with a more aggressive phenotype in vivo. , 1992, British Journal of Cancer.

[39]  I Nicoletti,et al.  A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry. , 1991, Journal of immunological methods.

[40]  N. Niederle,et al.  Development and mechanisms of interferon resistance. , 1990, Cancer treatment reviews.

[41]  K. Isselbacher,et al.  Abnormal structure and expression of p53 gene in human hepatocellular carcinoma. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[42]  B. Dupont,et al.  Standardization of the human in vitro cell-mediated lympholysis technique. , 2008, Tissue antigens.